ABACAVIR SULFATE

Post-LOESM

abacavir

ANDAORALSOLUTION
Approved
Sep 2016
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

[See Microbiology ()] .

Clinical Trials (5)

NCT03685500Phase 4Completed

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

Started Dec 2018
78 enrolled
HIV Infections
NCT02957864Phase 4Unknown

Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide

Started Oct 2016
80 enrolled
Renal Insufficiency,ChronicHivTherapeutic Agent Toxicity
NCT02603107Phase 3Completed

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Started Nov 2015
578 enrolled
HIV-1 Infection
NCT02607930Phase 3Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Started Nov 2015
631 enrolled
HIV-1 Infection
NCT02539576Phase 1Completed

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Started Oct 2015
12 enrolled
Infection, Human Immunodeficiency Virus